Prescribing hormone replacement therapy for menopausal symptoms

Annals of Internal Medicine

Volumn 131, Issue 8, 1999, Pages 605-616

  McNagny, Sally E ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; CASE REPORT; FEMALE; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; MENOPAUSE; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; TREATMENT INDICATION;

EID: 0032742152     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-131-8-199910190-00010     Document Type: Review

References (181)

1. Johnson SR. Menopause and hormone replacement therapy. Med Clin North Am. 1998;82:297-320.
2. Greendale GA, Lee NP, Arriola ER. The menopause. Lancet. 1999;353: 571-80.
3. McKinlay SM, Brambilla DJ, Posner JG. The normal menopause transition. Maturitas. 1992;14:103-15.
4. Whelan EA, Sandler DP, McConnaughey DR, Weinberg CR. Menstrual and reproductive characteristics and age at natural menopause. Am J Epidemiol. 1990;131:625-32.
5. Matthews KA. Myths and realities of the menopause. Psychosom Med. 1992,54:1-9.
6. Age at Menopause. Public Health Service Publication No. 1000 (Series 11, No.19). Washington, DC: U.S. Department of Health Education and Welfare: 1966.
7. Greendale GA, Sowers M. The menopause transition. Endocrinol Metab Clin North Am. 1997;26:261-77.
8. Lobo RA. Treatment of the Postmenopausal Woman: Basic and Clinical Aspects. New York: Raven Pr; 1994.
9. Berek JS, ed. Novak's Gynecology. 12th ed. Baltimore: Williams & Wilkins; 1996.
10. Speroff L, Glass RH, Kase NG. Clinical Gynecologic Endocrinology and Infertility. 5th ed. Baltimore: Williams & Wilkins; 1994.
11. ACOG criteria set. Ambulatory care criteria set: hormone replacement therapy. Number 23, April 1997 Committee on Quality Assessment. American College of Obstetricians and Gynecologists. Int J Gynaecol Obstet. 1997;57: 331-2.
12. American College of Obstetricians and Gynecologists. Hormone replacement therapy. ACOG Educational Bulletin. Washington, DC: American College of Obstetricians and Gynecologists; 1998.
13. Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med. 1992;117:1016-37.
14. Lip GY, Beevers M, Churchill D, Beevers DG. Hormone replacement therapy and blood pressure in hypertensive women. J Hum Hypertens. 1994; 8:491-4.
15. Wren BG, Routledge AD. The effect of type and dose of oestrogen on the blood pressure of post-menopausal women. Maturitas. 1983;5:135-42.
16. Effects of estrogen or estrogen/progestin regimers on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA. 1995; 273:199-208.
17. Grodstein F, Stampfer MJ, Goldhaber SZ, Manson JE, Colditz GA, Speizer FE, et al. Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet. 1996;348:983-7.
18. Jick H, Derby LE, Myers MW, Vasilakis C, Newton KM. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet. 1996;348:981-3.
19. Kudrow L. The relationship of headache frequency to hormone use in migraine. Headache. 1975;15:37-40.
20. MacGregor EA. Menstruation, sex hormones, and migraine. Neurol Clin. 1997;15:125-41.
21. American College of Obstetricians and Gynecologists. Hormone replacement therapy. Technical Bulletin, Vol. 166. Washington, DC: American College of Obstetricians and Gynecologists; 1992.
22. Treatment of estrogen deficiency symptoms in women surviving breast cancer. The Hormone Foundation, Canadian Breast Cancer Research Initiative, National Cancer Institute of Canada, Endocrine Society, and the University of Virginia Cancer and Women's Place. J Clin Endocrinol Metab. 1998;83: 1993-2000.
23. Cobleigh MA, Berris RF, Bush T, Davidson NE, Robert NJ, Sparano JA, et al. Estrogen replacement therapy in breast cancer survivors. A time for change. Breast Cancer Committees of the Eastern Cooperative Oncology Group. JAMA. 1994;272:540-4.
24. Eden J, Bush T, Nand W, Wren B. A case-control study of combined continuous estrogen-progestin replacement therapy among women with a personal history of breast cancer. Menopause: The Journal of the North American Menopause Society. 1995;2:67-72.
25. Weinstein L. Efficacy of a continuous estrogen-progestin regimen in the menopausal patient. Obstet Gynecol. 1987;69:929-32.
26. Weinstein L, Bewtra C, Gallagher JC. Evaluation of a continuous combined low-dose regimen of estrogen-progestin for treatment of the menopausal patient. Am J Obstet Gynecol. 1990;162:1534-42.
27. Eastell R. Treatment of postmenopausal osteoporosis. N Engl J Med. 1998; 338:736-46.
28. Grodstein F, Stampfer MJ, Manson JE, Colditz GA, Willett WC, Rosner B, et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med. 1996;335:453-61.
29. Grodstein F, Stampfer M. The epidemiology of coronary heart disease and estrogen replacement in postmenopausal women. Prog Cardiovasc Dis. 1995;38:199-210.
30. Heckbert SR, Weiss NS, Koepsell TD, Lemaitre RN, Smith NL, Siscovick DS, et al. Duration of estrogen replacement therapy in relation to the risk of incident myocardial infarction in postmenopausal women. Arch Intern Med. 1997;157:1330-6.
31. Rosenberg L, Palmer JR, Shapiro S. A case-control study of myocardial infarction in relation to use of estrogen supplements. Am J Epidemiol. 1993; 137:54-63.
32. Stampfer MJ, Colditz GA, Willett WC, Manson JE, Rosner B, Speizer FE, et al. Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses' health study. N Engl J Med. 1991;325: 756-62.
33. Sullivan JM, Fowlkes LP. The clinical aspects of estrogen and the cardiovascular system. Obstet Gynecol. 1996;87:36S-43S.
34. Wild RA. Estrogen: effects on the cardiovascular tree. Obstet Gynecol. 1996;87:27S-35S.
35. Sotelo MM, Johnson SR. The effects of hormone replacement therapy on coronary heart disease. Endocrinol Metab Clin North Am. 1997;26:313-28.
36. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med. 1991;20:47-63.
37. Yaffe K, Sawaya G, Lieberburg I, Grady D. Estrogen therapy in postmenopausal women: effects on cognitive function and dementia. JAMA. 1998;279:688-95.
38. Kronenberg F. Hot flashes: epidemiology and physiology. Ann N Y Acad Sci. 1990;592:52-86.
39. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer, Lancet. 1997;350:1047-59.
40. European consensus development conference on menopause. European Menopause Society. Hum Reprod. 1996;11:975-9.
41. Steinberg KK, Thacker SB, Smith SJ, Stroup DF, Zack MM, Flanders WD, et al. A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA. 1991;265:1985-90.
42. Effectiveness and Costs of Osteoporosis Screening and Hormone Replacement Therapy. Washington, DC. Congress Office of Technology Assessment, Congress of the United States; 1995.
43. Daly E, Vessey MP, Hawkins MM, Carson JL, Gough P, Marsh S. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet. 1996;348:977-80.
44. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. JAMA. 1998;280:605-13.
45. Belchetz PE. Hormonal treatment of postmenopausal women. N Engl J Med. 1994;330:1062-71.
46. Col NF, Eckman MH, Karas RH, Pauker SG, Goldberg RJ, Ross EM, et al. Patient-specific decisions about hormone replacement therapy in postmenopausal women. JAMA. 1997;277:1140-7.
47. Hammond CB. Menopause and hormone replacement therapy: an overview. Obstet Gynecol. 1996;87:2S-15S.
48. Klein R, Berlin L. Benefits and risks of hormone replacement therapy. In: Pavlik EJ, ed. Estrogens, Progestins, and Their Antagonists. Boston: Birkhauser; 1996:1-50.
49. Sowers MR, La Pietra MT. Menopause: its epidemiology and potential association with chronic diseases Epidemiol Rev. 1995;17:287-302.
50. Udoff L, Langenberg P, Adashi EY. Combined continuous hormone replacement therapy: a critical review. Obstet Gynecol. 1995;86:306-16.
51. U.S. Preventive Services Task Force. Guide to Clinical Preventive Services. 2d ed. Baltimore: Williams & Wilkins; 1996.
52. Anderson KM, Wilson PW, Odell PM, Kannel WB. An updated coronary risk profile. A statement for health professionals. Circulation. 1991;83:356-62.
53. Hemminki E, Sihvo S. A review of postmenopausal hormone therapy recommendations: potential for selection bias. Obstet Gynecol. 1993;82: 1021-8.
54. Barrett-Connor E, Grady D. Hormone replacement therapy, heart disease, and other considerations. Annu Rev Public Health. 1998;19:55-72.
55. Posthuma WF, Westendorp RG, Vandenbroucke JP. Cardioprotective effect of hormone replacement therapy in postmenopausal women: is the evidence biased? BMJ. 1994;308:1268-9.
56. Chung TK, Yip SK, Lam P, Chang AM, Haines CJ. A randomized, double-blind, placebo-controlled, crossover study on the effect of oral oestradiol on acute menopausal symptoms. Maturitas. 1996;25:115-23.
57. Haas S, Walsh B, Evans S, Krache M, Ravnikar V, Schiff I. The effect of transdermal estradiol on hormone and metabolic dynamics over a six-week period. Obstet Gynecol. 1988;71:671-6.
58. Marchesoni D, Fiscon D, Bologna A, Dal Pozzo M, Dal Magro L, Mozzanega B. Transdermal estrogen therapy in menopause. Eighteen months follow-up. Clin Exp Obstet Gynecol. 1991;18:281-5.
59. Sporrong T, Hellgren M, Samsioe G, Mattsson LA. Metabolic effects of continuous estradiol-progestin therapy in postmenopausal women. Obstet Gynecol. 1989;73(5 Pt 1):754-8.
60. Felson DT, Zhang Y, Hannan MT, Kiel DP, Wilson PW, Anderson JJ. The effect of postmenopausal estrogen therapy on bone density in elderly women. N Engl J Med. 1993;329:1141-6.
61. Lufkin EG, Wahner HW, O'Fallon WM, Hodgson SF, Kotowicz MA, Lane AW, et al. Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med. 1992;117:1-9.
62. Crook D, Cust MP, Gangar KF, Worthington M, Hillard TC, Stevenson JC, et al. Comparison of transdermal and oral estrogen-progestin replacement therapy: effects on serum lipids and lipoproteins. Am J Obstet Gynecol. 1992;166:950-5.
63. Karjalainen A, Heikkinen J, Savolainen MJ, Backstrom AC, Salinto M, Kesaniemi YA. Metabolic changes induced by peroral oestrogen and transdermal oestradiol gel therapy. Br J Obstet Gynaecol. 1997;104(Suppl 16):38-43.
64. Stevenson JC, Crook D. Godsland IF, Lees B, Whitehead MI. Oral versus transdermal hormone replacement therapy. Int J Fertil Menopausal Stud. 1993;38(Suppl 1):30-5.
65. Hebert-Croteau N. A meta-analysis of hormone replacement therapy and colon cancer in women. Cancer Epidemiol Biomarkers Prev. 1998;7:653-9.
66. McBee WL, Dailey ME, Dugan E, Shumaker SA. Hormone replacement therapy and other potential treatments for dementias. Endocrinol Metab Clin North Am. 1997;26:329-45.
67. Staropoli CA, Flaws JA, Bush TL, Moulton AW. Predictors of menopausal hot flashes. J Womens Health. 1998;7:1149-55.
68. Hendrix SL. Nonestrogen management of menopausal symptoms. Endocrinol Metab Clin North Am. 1997;26:379-90.
69. Clayden JR, Bell JW, Pollard P. Menopausal flushing: double-blind trial of a non-hormonal medication. Br Med J. 1974;1:409-12.
70. Loprinzi CL, Michalak JC, Quella SK, O'Fallon JR, Hatfield AK, Nelimark RA, et al. Megestrol acetate for the prevention of hot flashes. N Engl J Med. 1994;331:347-52.
71. Nagamani M, Kelver ME, Smith ER. Treatment of menopausal hot flashes with transdermal administration of clonidine. Am J Obstet Gynecol. 1987; 156:561-5.
72. Albertazzi P, Pansini F, Bonaccorsi G, Zanotti L, Forini E, De Aloysio O. The effect of dietary soy supplementation on hot flushes. Obstet Gynecol. 1998;91:6-11.
73. Physicians' Desk Reference. Montvale, NJ: Medical Economics Data Production Co; 1998.
74. Lindsay R. The role of estrogen in the prevention of osteoporosis. Endocrinol Metab Clin North Am. 1998;27:399-409.
75. National Osteoporosis Foundation. Physician's Guide to Prevention and Treatment of Osteoporosis. Washington, DC: National Osteoporosis Foundation; 1998.
76. Genant HK, Lucas J, Weiss S, Akin M, Emkey R, McNaney-Flint H. et al. Low-dose esterified estrogen therapy: effects on bone, plasma estradiol concentrations, endometrium, and lipid levels. Estratab/Osteoporosis Study Group. Arch Intern Med. 1997;157:2609-15.
77. Miller VT, Muesing RA, LaRosa JC, Stoy DB, Fowler SE, Stillman RJ. Quantitative and qualitative changes in lipids, lipoproteins, apolipoprotein A-I, and sex hormone-binding globulin due to two doses of conjugated equine estrogen with and without a progestin. Obstet Gynecol. 1994;83: 173-9.
78. Speroff L, Rowan J, Symons J, Genant H, Wilborn W. The comparative effect on bone density, endometrium, and lipids of continuous hormones as replacement therapy (CHART study). A randomized controlled trial. JAMA. 1996;276:1397-403.
79. Watts NB, Notelovitz M, Timmons MC, Addison WA, Wiita B, Downey LJ. Comparison of oral estrogens and estrogens plus androgen on bone mineral density, menopausal symptoms, and lipid-lipoprotein profiles in surgical menopause. Obstet Gynecol. 1995;85:529-37.
80. Chae CU, Ridker PM, Manson JE. Postmenopausal hormone replacement therapy and cardiovascular disease. Thromb Haemost. 1997;78:770-80.
81. Miller VI, Muesing RA, LaRosa JC, Stoy DB, Phillips EA, Stillman RJ. Effects of conjugated equine estrogen with and without three different progestogens on lipoproteins, high-density lipoprotein subfractions, and apolipoprotein A-I. Obstet Gynecol. 1991;77:235-40.
82. Taitel H, Kafrissen ME. Norethindrone - a review of therapeutic applications. Int J Fertil Menopausal Stud. 1995;40:207-23.
83. Raz R, Stamm WE. A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections. N Engl J Med. 1993; 329:753-6.
84. Hemminki E, McPherson K. Impact of postmenopausal hormone therapy on cardiovascular events and career: pooled data from clinical trials. BMJ. 1997;315:149-53.
85. Sidney S, Petitti D, Quesenberry C Jr. Myocardial infarction and the use of estrogen and estrogen-progestogen in postmenopausal women. Ann Intern Med. 1997;127:501-8.
86. Petitti DB. Hormone replacement therapy and heart disease prevention: experimentation trumps observation [Editorial]. JAMA. 1998;280:650-2.
87. Hemminki E, Malin M, Topo P. Selection to postmenopausal therapy by women's characteristics. J Clin Epidemiol. 1993;46:211-9.
88. Matthews KA, Kuller LH, Wing RR, Meilahn EN, Plantinga P. Prior to use of estrogen replacement therapy, are users healthier than nonusers? Am J Epidemiol. 1996;143:971-8.
89. Barrett-Connor E. Rethinking estrogen and the brain [Editorial]. J Am Geriatr Soc. 1998;46:918-20.
90. Birge SJ, Mortel KF. Estrogen and the treatment of Alzheimer's disease. Am J Med. 1997;103:36S-45S.
91. Henderson VW. The epidemiology of estrogen replacement therapy and Alzheimer's disease. Neurology. 1997;48(5 Suppl 7):S27-35.
92. Rice MM, Graves AB, McCurry SM, Larson EB. Estrogen replacement therapy and cognitive function in postmenopausal women without dementia. Am J Med. 1997;103:26S-35S.
93. Ditkoff EC, Crary WG, Cristo M, Lobo RA. Estrogen improves psychological function in asymptomatic postemenopausal women. Obstet Gynecol. 1991;78:991-5.
94. Grodstein F, Martinez ME, Platz EA, Giovannucci E, Colditz GA, Kautzky M, et al. Postmenopausal hormone use and risk for colorectal cancer and adenoma. Ann Intern Med. 1998;128:705-12.
95. Kampman E, Potter JD, Slattery ML, Caan BJ, Edwards S. Hormone replacement therapy, reproductive history, and colon cancer: a multicenter, case-control study in the United States. Cancer Causes Control. 1997;8:146-58.
96. Troisi R, Schairer C, Chow WH, Schatzkin A, Brinton LA, Fraumeni JF Jr. A prospective study of menopausal hormones and risk of coloreclal cancer. Cancer Causes and Control. 1997;8:130-8.
97. Calle EE. Hormone replacement therapy and coloreclal cancer: interpreting the evidence [Editorial]. Cancer Causes Control. 1997;8:127-9.
98. Falkeborn M, Persson I, Adami HO, Bergstrom R, Eaker E, Lithell H, et al. The risk of acute myocardial infarction after oestrogen and oestrogen-progestogen replacement. Br J Obstet Gynaecol. 1992;99:821-8.
99. Fung MM, Barrett-Conner E, Bettencourt RR. Hormone replacement therapy and stroke risk in older women. J Womens Health. 1999;8:359-64.
100. Pedersen AT, Lidegaard O, Kreiner S, Ottesen B. Hormone replacement therapy and risk of non-fatal stroke. Lancet. 1997;350:1277-83.
101. Thom DH, Brown JS. Reproductive and hormonal risk factors for urinary incontinence in later life: a review of the clinical and epidemiologic literature. J Am Geriatric Soc. 1998;46:1411-7.
102. Dunn LB, Damesyn M, Moore AA, Reuben DB, Greendale GA. Does estrogen prevent skin aging? Results from the First National Health and Nutrition Examination Survey (NHANES I). Arch Dermatol. 1997;133:339-42.
103. Grady D, Gebretsadik T, Kerlikowske K, Ernster V, Petitti D. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol. 1995;85:304-13.
104. Thorneycroft IH. Practical aspects of hormone replacement therapy. Prog Cardiovasc Dis. 1995;38:243-54.
105. AACE clinical practice guidelines for the prevention and treatment of postmenopausal osteoporosis. American Association of Clinical Endocrinologists. Endocrine Practice. 1996;2:157-71.
106. Andrews WC. Progestin dosage in hormone replacement therapy. ACOG Clin Review. 1996;1:1.
107. Woodruff J, Pickar JH. Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterone acetate or conjugated estrogens alone. The Menopause Study Group. Am J Obstet Gynecol. 1994;170(5 Pt 1):1213-23.
108. Randomised comparison of oestrogen versus oestrogen plus progestogen hormone replacement therapy in women with hysterectomy. Medical Research Council's General Practice Research Framework. BMJ. 1996;312:473-8.
109. MacLennan AH, MacLennan A, Wenzel S, Chambers HM, Eckert K. Continuous low-dose oestrogen and progestogen hormone replacement therapy: a randomised trial. Med J Aust. 1993;159:102-6.
110. Whitehead MI, Hillard TC, Crook D. The role and use of progestogens. Obstet Gynecol. 1990;75(4 Suppl):59S-76S.
111. Bolaji II, Mortimer G, Grimes H, Talion DF, O'Dwyer E, Fottrell PF. Clinical evaluation of near-continuous oral micronized progesterone therapy in estrogenized postmenopausal women. Gynecol Endocrinol. 1996;10:41-7.
112. Gillet JY, Andre G, Faguer B, Erny R, Buvat-Herbaut M, Domin MA, et al. Induction of amenorrhea during hormone replacement therapy: optimal micronized progesterone dose. A multicenter study. Maturitas. 1994; 19:103-15.
113. Hargrove JT, Eisenberg E. Menopause. Med Clin North Am. 1995;79: 1337-56
114. Fanchin R, De Ziegler D, Bergeron C, Righini C, Torrisi C, Frydman R. Transvaginal administration of progesterone. Obstet Gynecol. 1997;90:396-401.
115. Ross D, Cooper AJ, Pryse-Davies J, Bergeron C Collins WP, Whitehead MI. Randomized, double-blind, dose-ranging study of the endometrial effects of a vaginal progesterone gel in estrogen-treated postmenopausal women. Am J Obstet Gynecol. 1997;177:937-41.
116. Gapstur SM, Morrow M, Sellers TA. Hormone replacement therapy and risk of breast cancer with a favorable histology: results of the Iowa Women's Health Study. JAMA. 1999;281:2091-7.
117. Berkowitz GS, Kelsey JL, Holford TR, LiVolsi VA, Merino MJ, Beck GJ, et al. Estrogen replacement therapy and fibrocystic breast disease in postmenopausal women. Am J Epidemiol. 1985;121:238-45.
118. Berkowitz GS, Kelsey JL, LiVolsi VA, Merino MJ, Holford TR, Hildreth NG, et al. Exogenous hormone use and fibrocystic breast disease by histopathologic component. Int J Cancer. 1984;34:443-9.
119. Jick SS, Walker AM, Jick H. Conjugated estrogens and fibrocystic breast disease. Am J Epidemiol. 1986;124746-51.
120. Trapido EJ, Brinton LA, Schairer C, Hoover R. Estrogen replacement therapy and benign breast disease. J Natl Cancer Inst. 1984;73:1101-5.
121. Beresford SA, Weiss NS, Voigt LF, McKnight B. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women. Lancet. 1997;349:458-61.
122. Laya MB, Larson EB, Taplin SH, White E. Effect of estrogen replacement therapy on the specificity and sensitivity of screening mammography. J Nat Cancer Inst. 1996;88:643-9.
123. Stomper PC, Van Voorhis BJ, Ravnikar VA, Meyer JE. Mammographic changes associated with postmenopausal hormone replacement therapy: a longitudinal study. Radiology. 1990;174:487-90.
124. Design of the Women's Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Control Clin Trials. 1998;19:61-109.
125. Hasler CM, Finn SC. Soy: just a hill of beans? J Womens Health. 1998;7: 519-23.
126. Nagata C, Takatsuka N, Inaba S, Kawakami N, Shimizu H. Association of diet and other lifestyle with onset of menopause in Japanese women. Maturitas. 1998;29:105-13.
127. Knight DC, Eden JA. A review of the clinical effects of phytoestrogens. Obstet Gynecol. 1996;87(5 Pt 2):897-904.
128. Anderson JW, Johnstone BM, Cook-Newell ME. Meta-analysis of the effects of soy protein intake on serum lipids. N Engl J Med. 1995;333:276-82.
129. Seidl MM, Stewart DE. Alternative treatments for menopausal symptoms. Qualitative study of women's experiences. Can Fam Physician. 1998;44: 1271-6.
130. Taylor M. Alternatives to conventional hormone replacement therapy. Compr Ther. 1997;23:514-32.
131. Murkies AL, Wilcox G, Davis SR. Clinical review 92: Phytoestrogens. J Clin Endocrinol Metab. 1998;83:297-303.
132. Kaunitz AM. The role of androgens in menopausal hormonal replacement. Endocrinol Metab Clin North Am. 1997;26:391-7.
133. Sarrel P, Dobay B, Wiita B. Estrogen and estrogen-androgen replacement in postmenopausal women dissatisfied with estrogen-only therapy. Sexual behavior and neuroendocrine responses. J Reprod Med. 1998;43:847-56.
134. Abraham D, Carpenter PC. Issues concerning androgen replacement therapy in postmenopausal women. Mayo Clin Proc 1997;72:1051-5.
135. Gelfand MM, Wiita B. Androgen and estrogen-androgen hormone replacement therapy: a review of the safety literature, 1941 to 1996. Clin Ther. 1997;19:383-404.
136. Casson PR, Carson SA. Androgen replacement therapy in women: myths and realities. Int J Fertil Menopausal Stud. 1996;41:412-22.
137. MacGregor JI, Jordan VC. Basic guide to the mechanisms of antiestrogen action. Phamacol Rev. 1998;50:151-96.
138. Spencer CP, Morris EP, Rymer JM. Selective estrogen receptor modulators: women's panacea for the next millennium? Am J Obstet Gynecol. 1999;180(3 Pt 1):763-70.
139. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90:1371-88.
140. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet. 1998;351:1451-67.
141. Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med. 1998;339:1609-18.
142. Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA. 1999;281:2189-97.
143. Barrett-Conner E, Wenger NK, Grady D, Mosca L, Collins P, Kornitzer M, et al. Hormone and nonhormone therapy for the maintenance of postmenopausal health: the need for randomized controlled trials of estrogen and raloxifene. J Womens Health. 1998;7:839-47.
144. Khovidhunkit W, Shoback DM. Clinical effects of raloxifene hydrochloride in women. Ann Intern Med. 1999;130:431-9.
145. Lobo R. The role of progestins in hormone replacement therapy. Am J Obstet Gynecol. 1992;166(6 Pt 2):1997-2004.
146. Top 200 Rx Drugs. In: Drug Topics Red Book. Montvale, NJ: Medical Economics; 1996:98.
147. Wysowski DK, Golden L, Burke L. Use of menopausal estrogens and medroxyprogesterone in the United States, 1982-1992. Obstet Gynecol. 1995;85:6-10.
148. Barrett-Connor E. Prevalence, initiation, and continuation of hormone replacement therapy. J Womens Health. 1995;4:143-8.
149. Berman R, Epstein R, Lydick E. Compliance of women in taking estrogen replacement therapy. J Womens Health. 1996;5:213-20.
150. Berman RS, Epstein RS, Lydick E. Risk factors associated with women's compliance with estrogen replacement therapy. J Womens Health. 1997;6: 219-26.
151. Nachtigall LE. Enhancing patient compliance with hormone replacement therapy at menopause. Obstet Gynecol. 1990;75(4 Suppl):77S-80S.
152. Stumpf PG, Trolice MP. Compliance problems with hormone replacement therapy. Obstet Gynecol Clin North Am. 1994;21:219-29.
153. Evans MP, Fleming KC, Evans JM. Hormone replacement therapy: management of common problems. Mayo Clin Proc. 1995;70:800-5.
154. Marsh MS, Whitehead MI. Management of the menopause. Br Med Bull. 1992;48:426-57.
155. Sulak PJ. Endometrial cancer and hormone replacement therapy. Appropriate use of progestins to oppose endogenous and exogenous estrogens. Endocrinol Metab Clin North Am. 1997;26:399-412.
156. Greendale GA, Reboussin BA, Hogan P, Barnabei VM, Shumaker S, Johnson S, et al. Symptom relief and side effects of postmenopausal hormones: results from the Postmenopausal Estrogen/Progestin Interventions Trial. Obstet Gynecol. 1998;92:982-8.
157. Conor SL. A decade of experience with transdermal estrogen replacement therapy: overview of key pharmacologic and clinical findings. Int J Fertil. 1993;38:79-91.
158. Lufkin EG, Ory SJ. Relative value of transdermal and oral estrogen therapy in various clinical situations. Mayo Clin Proc. 1994;69:131-5.
159. Petitti DB, Sidney S, Perlman JA. Increased risk of cholecystectomy in users of supplemental estrogen. Gastroenterology. 1988;94:91-5.
160. Silberstein SD, Merriam GR. Estrogens, progestins, and headache. Neurology. 1991;41:786-93.
161. von Schoultz B. Climacteric complaints as influenced by progestogens. Maturitas. 1985;8:107-12.
162. Ettinger B, Selby J, Citron JT, Vangessel A, Ettinger VM, Hendrickson MR. Cyclic hormone replacement therapy using quarterly progestin. Obstet Gynecol. 1994;83(5 Pt 1):693-700.
163. Ettinger B. Use of low-dosage 17 beta-estradiol for the prevention of osteoporosis. Clin Ther. 1993;15:950-62.
164. Recker RR, Davies KM, Dowd RM, Heaney RP. The effect of low-dose continuous estrogen and progesterone therapy with calcium and vitamin D on bone in elderly women. A randomized, controlled trial. Ann Intern Med. 1999;130:897-904.
165. Ettinger B, Genant HK, Cann CE. Postmenopausal bone loss is prevented by treatment with low-dosage estrogen with calcium. Ann Intern Med. 1987;106:40-5.
166. Trabal J, Lenihan JJ, Melchione T, Stoltz R, Khairi S, Yang H, et al. Low-dose unopposed estrogens: preliminary findings on the frequency and duration of vaginal bleeding in postmenopausal women receiving esterified estrogens over a two-year period. Menopause. 1997;4:130-8.
167. Cushing KL, Weiss NS, Voigt LF, McKnight B, Beresford SA. Risk of endometrial cancer in relation to use of low-dose, unopposed estrogens. Obstet Gynecol. 1998;91:35-9.
168. Archer DF, Pickar JH, Bottiglioni F. Bleeding patterns in postmenopausal women taking continuous combined or sequential regimens of conjugated estrogens with medroxyprogesterone acetate. Menopause Study Group. Obstet Gynecol. 1994;83(5 Pt 1):686-92.
169. Spencer CP, Cooper AJ, Whitehead MI. Management of abnormal bleeding in women receiving hormone replacement therapy. BMJ. 1997;315:37-42.
170. Nand SL, Webster MA, Baber R, O'Connor V. Bleeding pattern and endometrial changes during continuous combined hormone replacement therapy. The Ogen/Provera Study Group. Obstet Gynecol. 1998;91(5 Pt 1): 678-84.
171. Williams SR, Frenchek B, Speroff T, Speroff L. A study of combined continuous ethinyl estradiol and norethindrone acetate for postmenopausal hormone replacement. Am J Obstet Gynecol. 1990;162:438-46.
172. Guidelines for counseling postmenopausal women about preventive hormone therapy. American College of Physicians. Ann Intern Med. 1992;117: 1038-41.
173. Ettinger B, Li DK, Klein R. Unexpected vaginal bleeding and associated gynecologic care in postmenopausal women using hormone replacement therapy: comparison of cyclic versus continuous combined schedules. Fertil Steril. 1998;69:865-9.
174. Goldstein SR, Nachtigall M, Snyder JR, Nachtigall L. Endometrial assessment by vaginal ultrasonography before endometrial sampling in patients with postmenopausal bleeding. Am J Obstet Gynecol. 1990;163(1 Pt 1):119-23.
175. Granberg S, Wikland M, Karlsson B, Norstrom A, Friberg LG. Endometrial thickness as measured by endovaginal ultrasonography for identifying endometrial abnormality. Am J Obstet Gynecol. 1991;164(1 Pt 1):47-52.
176. Langer RD, Pierce JJ, O'Hanlan KA, Johnson SR, Espeland MA, Trabal JF, et al. Transvaginal ultrasonography compared with endometrial biopsy for the detection of endometrial disease. Postmenopausal Estrogen/Progestin Interventions Trial. N Engl J Med. 1997;337:1792-8.
177. Lin MC, Gosink BB, Wolf SI, Feldesman MR, Stuenkel CA, Braly PS, et al. Endometrial thickness after menopause: effect of hormone replacement. Radiology, 1991;180:427-32.
178. Meuwissen JH, van Langen H, Moret E, Navarro-Morquecho I. Monitoring of oestrogen replacement therapy by vaginosonography of the endometrium. Maturitas. 1992;15:33-7.
179. Nasri MN, Coast GJ. Correlation of ultrasound findings and endometrial histopathology in postmenopausal women. Br J Obstet Gynaecol. 1989;96: 1333-8.
180. Smith-Bindman R, Kerlikowske K, Feldstein VA, Subak L, Scheidler J, Segal M, et al. Endovaginal ultrasound to exclude endometrial cancer and other endometrial abnormalities. JAMA. 1998;280:1510-7.
181. Varner RE, Sparks JM, Cameron CD, Roberts LL, Soong SJ. Transvaginal sonography of the endometrial in postmenopausal women. Obstet Gynecol. 1991;78:195-9.